Roche has posted a snapshot from a closely-watched Phase III trial of its TIGIT antibody after an “inadvertent disclosure.” Although the overall survival data are still not mature, analysts believe the numbers so far point to a positive trend in non-small cell lung cancer.
At the second interim analysis of…
Click here to view original post
